NASDAQ$NUVL
Nuvalent Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Nuvalent reported second quarter 2022 financial results and highlighted execution across its pipeline of novel kinase inhibitors.
Nuvalent reported a net loss of $18.5 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $257.0 million as of June 30, 2022, which is expected to fund operations into 2024. The company is advancing its pipeline with clinical trials ongoing for NVL-520 and NVL-655 and expects to select two additional development candidates in 2022.
- Preliminary dose escalation data expected in second half of 2022 from the ARROS-1 study of NVL-520 for advanced ROS1 positive NSCLC and other solid tumors.
- Dosing initiated and enrollment ongoing in ALKOVE-1 trial evaluating NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors.
- New NVL-655 preclinical data presented at IASLC 2022 World Conference on Lung Cancer Annual Meeting.
- Nuvalent is on track to select two additional development candidates from discovery pipeline in 2022.
Headline financials
Revenue & EPS history
Nuvalent · Revenue · Quarterly
$6M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2022
-0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-7.7%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+14.6%
Q4 2021
Best reaction
-5.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.5% | -4.1% | -7.5% | |
| Q3 2025 | -5.0% | -11.6% | +6.2% | |
| Q1 2025 | +3.2% | +3.7% | +10.2% | |
| Q4 2024 | -2.8% | -7.0% | -5.2% | |
| Q3 2024 | -4.3% | -8.0% | -8.0% | |
| Q1 2024 | -3.1% | +0.7% | +17.2% | |
| Q4 2023 | -1.4% | +0.6% | -13.3% | |
| Q3 2023 | +3.7% | +5.0% | +38.8% | |
| Q2 2023 | -1.1% | -3.1% | +9.2% | |
| Q1 2023 | -2.5% | -1.1% | +3.5% | |
| Q4 2022 | +8.3% | +4.7% | +0.9% | |
| Q3 2022 | +1.0% | +2.9% | -2.1% | |
| Q2 2022 | +4.5% | +9.3% | +13.1% | |
| Q1 2022 | -0.7% | +7.3% | +16.1% | |
| Q4 2021 | +14.6% | +20.2% | -8.1% | |
| Q3 2020 | +1.3% | -14.7% | -2.4% | |
| Q3 2021 | +1.3% | -10.4% | -20.1% | |
| Q2 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2021 | -4.3% | -2.9% | -52.6% | |
| Q2 2021 | -4.3% | -2.9% | -52.6% | |
| Q4 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro